BCTX (BriaCell Therapeutics) Interest Expense : $0.00 Mil (TTM As of Jan. 2025)

View and export this data going back to 2023. Start your Free Trial

What is BriaCell Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BriaCell Therapeutics's interest expense for the three months ended in Jan. 2025 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jan. 2025 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BriaCell Therapeutics's Operating Income for the three months ended in Jan. 2025 was $ -7.17 Mil. BriaCell Therapeutics's Interest Expense for the three months ended in Jan. 2025 was $ 0.00 Mil. BriaCell Therapeutics has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

BriaCell Therapeutics Interest Expense Historical Data

The historical data trend for BriaCell Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Interest Expense Chart

BriaCell Therapeutics Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

Interest Expense

Get a 7-Day Free Trial

-0.03

-0.08

BriaCell Therapeutics Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

BriaCell Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

BriaCell Therapeutics (NAS:BCTX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BriaCell Therapeutics's Interest Expense for the three months ended in Jan. 2025 was $0.00 Mil. Its Operating Income for the three months ended in Jan. 2025 was $-7.17 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jan. 2025 was $0.00 Mil.

BriaCell Therapeutics's Interest Coverage for the quarter that ended in Jan. 2025 is calculated as

BriaCell Therapeutics had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

BriaCell Therapeutics Corp has no debt.

BriaCell Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

8BT0:Germany BCT:Canada

Address

235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Executives

Marc Lustig	director	4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3
Jamieson Bondarenko	director	402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub	director	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin	officer: CFO & Secretary	MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del	officer: Chief Medical Officer	44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams	director, officer: President & CEO	620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg	director	201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago	officer: Chief Scientific Officer	2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony	director	P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0